Arthur M Krieg

List of Publications by Year in Descending Order

192 papers	23,980 citations	74 h-index	153 g-index
201 ext. papers	25,253 ext. citations	8.1 avg, IF	7.13 L-index

#	Paper	IF	Citations
192	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. *Cancer Discovery*, **2021**,	24.4	17
191	Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. *Journal of Immunology*, **2020**, 204, 1386-1394	5.3	20
190	Rigging Innate Immunity against the Flu. *Molecular Therapy*, **2017**, 25, 1993-1994	11.7	
189	The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. *Microbial Pathogenesis*, **2013**, 63, 16-8	3.8	3
188	CpG still rocks! Update on an accidental drug. *Nucleic Acid Therapeutics*, **2012**, 22, 77-89	4.8	153
187	Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E797-803	11.5	82
186	Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. *Journal of Infectious Diseases*, **2012**, 205, 1294-304	7	74
185	Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. *Immunobiology*, **2011**, 216, 12-23	3.4	10
184	Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. *Journal of Infectious Diseases*, **2011**, 204, 636-44	7	21
183	Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. *Nucleic Acid Therapeutics*, **2011**, 21, 201-14	4.8	19
182	A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. *Oligonucleotides*, **2010**, 20, 93-101		58
181	Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. *Progress in Respiratory Research*, **2010**, 95-99		2
180	Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. *Comparative Immunology, Microbiology and Infectious Diseases*, **2010**, 33, e111-7	2.6	7
179	Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. *Expert Opinion on Drug Discovery*, **2009**, 4, 587-603	6.2	6
178	AIMing 2 detect foreign DNA. *Science Signaling*, **2009**, 2, pe39	8.8	8
177	Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. *International Immunology*, **2009**, 21, 607-19	4.9	33
176	Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. *Cancer Immunology, Immunotherapy*, **2009**, 58, 615-28	7.4	77

175	NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. *Microbes and Infection*, **2009**, 11, 49-56	9.3	18
174	Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. *Advanced Drug Delivery Reviews*, **2009**, 61, 195-204	18.5	446
173	CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. *Vaccine*, **2009**, 27, 2220-9	4.1	25
172	A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. *Vaccine*, **2008**, 26, 4849-59	4.1	54
171	Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFNalpha-producing cells and TLR9 mRNA expression. *Veterinary Immunology and Immunopathology*, **2008**, 123, 324-36	2	15
170	CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. *Veterinary Immunology and Immunopathology*, **2008**, 126, 273-82	2	11
169	Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. *Journal of Immunology*, **2008**, 180, 3729-38	5.3	225
168	Immunology. The toll of cathepsin K deficiency. *Science*, **2008**, 319, 576-7	33.3	11
167	Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. *Journal of Clinical Oncology*, **2008**, 26, 3979-86	2.2	142
166	Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. *Infection and Immunity*, **2008**, 76, 2895-904	3.7	64
165	Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. *Vaccine Journal*, **2008**, 15, 221-6		16
164	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. *Blood*, **2008**, 112, 3508-16	2.2	67
163	Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. *Journal of Immune Based Therapies and Vaccines*, **2008**, 6, 3		15
162	Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. *Clinical Cancer Research*, **2007**, 13, 6168-74	12.9	102
161	PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC). *Journal of Thoracic Oncology*, **2007**, 2, S461	8.9	6
160	Stimulation of Toll-Like Receptor 9 for Enhancing Vaccination **2007**, 43-66		
159	Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. *International Journal of Cancer*, **2007**, 121, 1520-8	7.5	40
158	Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. *Immunology*, **2007**, 120, 526-35	7.8	46

157	Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. *Immunological Reviews*, **2007**, 220, 251-69	11.3	270
156	Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. *Cellular Immunology*, **2007**, 250, 75-84	4.4	68
155	TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. *Journal of Immunology*, **2007**, 179, 3937-46	5.3	86
154	Antiinfective applications of toll-like receptor 9 agonists. *Proceedings of the American Thoracic Society*, **2007**, 4, 289-94		78
153	Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. *Journal of Immunology*, **2007**, 179, 2493-500	5.3	106
152	Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. *Veterinary Immunology and Immunopathology*, **2007**, 115, 24-34	2	26
151	Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. *Veterinary Immunology and Immunopathology*, **2007**, 115, 357-68	2	10
150	The toll of too much TLR7. *Immunity*, **2007**, 27, 695-7	32.3	28
149	Development of TLR9 agonists for cancer therapy. *Journal of Clinical Investigation*, **2007**, 117, 1184-94	15.9	320
148	Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. *Antiviral Therapy*, **2007**, 12, 741-51	1.6	17
147	Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON), an Investigational Synthetic Toll-like Receptor 9 Agonist. *Antiviral Therapy*, **2007**, 12, 741-751	1.6	31
146	CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. *Cancer Immunology, Immunotherapy*, **2006**, 55, 515-27	7.4	25
145	Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. *Experimental Hematology*, **2006**, 34, 1403-12	3.1	23
144	Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. *European Journal of Immunology*, **2006**, 36, 1815-26	6.1	77
143	Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. *ChemMedChem*, **2006**, 1, 1007-14	3.7	29
142	High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. *Journal of Immunology*, **2006**, 177, 8701-7	5.3	55
141	Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. *Journal of Immunology*, **2006**, 177, 1028-39	5.3	66
140	Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. *Oligonucleotides*, **2006**, 16, 58-67		25

139	A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. *Infection and Immunity*, **2006**, 74, 1944-8	3.7	34
138	New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. *Journal of Immunology*, **2006**, 177, 1670-8	5.3	149
137	Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. *Journal of Clinical Oncology*, **2006**, 24, 5716-24	2.2	186
136	Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. *Journal of Pediatric Surgery*, **2006**, 41, 1361-8	2.6	23
135	Potential use of CpG ODN for cancer immunotherapy. *Update on Cancer Therapeutics*, **2006**, 1, 49-58		3
134	Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. *Vaccine*, **2006**, 24, 6155-62	4.1	25
133	Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. *Journal of Immunotherapy*, **2006**, 29, 558-68	5	124
132	Therapeutic potential of Toll-like receptor 9 activation. *Nature Reviews Drug Discovery*, **2006**, 5, 471-84	64.1	969
131	CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines **2006**, 87-110		4
130	CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. *Aids*, **2005**, 19, 1473-9	3.5	152
129	The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. *Journal of Virology*, **2005**, 79, 14355-70	6.6	112
128	Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. *Biochemical Pharmacology*, **2005**, 69, 981-91	6	29
127	CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. *Antiviral Research*, **2005**, 65, 87-95	10.8	44
126	Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. *European Journal of Immunology*, **2005**, 35, 273-81	6.1	48
125	Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. *Journal of Experimental Medicine*, **2005**, 202, 1575-85	16.6	436
124	Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. *Vaccine*		46
123	Antibody repertoire development in fetal and neonatal piglets. IX. Three pathogen-associated molecular patterns act synergistically to allow germfree piglets to respond to type 2 thymus-independent and thymus-dependent antigens. *Journal of Immunology*, **2005**, 175, 6772-85	5.3	37
122	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *Journal of Clinical Investigation*, **2005**, 115, 739-46	15.9	497

121	CpG Oligodeoxynucleotides for Mucosal Vaccines **2005**, 959-965		
120	Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. *Clinical Cancer Research*, **2005**, 11, 361-9	12.9	105
119	Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 2314-7	5.9	25
118	CpG oligodeoxynucleotide enhances tumor response to radiation. *Cancer Research*, **2004**, 64, 5074-7	10.1	127
117	Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. *Journal of Leukocyte Biology*, **2004**, 76, 585-93	6.5	14
116	Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. *Journal of Immunology*, **2004**, 172, 4926-33	5.3	213
115	CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. *Journal of Immunology*, **2004**, 173, 5148-55	5.3	91
114	CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. *Journal of Endotoxin Research*, **2004**, 10, 431-8		46
113	Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. *Infection and Immunity*, **2004**, 72, 4494-502	3.7	55
112	Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. *Journal of Endotoxin Research*, **2004**, 10, 247-51		31
111	CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. *Infection and Immunity*, **2004**, 72, 949-57	3.7	84
110	Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. *Immunology*, **2004**, 113, 212-23	7.8	119
109	Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. *Current Oncology Reports*, **2004**, 6, 88-95	6.3	182
108	Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. *European Journal of Immunology*, **2004**, 34, 251-62	6.1	480
107	Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). *Oligonucleotides*, **2004**, 14, 23-31		44
106	Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. *Journal of Immunology*, **2004**, 173, 4433-42	5.3	511
105	Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. *Vaccine*, **2004**, 22, 2641-50	4.1	8
104	C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. *Immunobiology*, **2004**, 209, 141-54	3.4	58

103	Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. *Journal of Immunotherapy*, **2004**, 27, 460-71	5	168
102	Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. *Oligonucleotides*, **2003**, 13, 143-50		22
101	Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. *International Immunology*, **2003**, 15, 223-31	4.9	40
100	Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. *Cancer Immunology, Immunotherapy*, **2003**, 52, 317-27	7.4	29
99	CpG motifs: the active ingredient in bacterial extracts?. *Nature Medicine*, **2003**, 9, 831-5	50.5	246
98	P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. *Oligonucleotides*, **2003**, 13, 491-9		38
97	CpG DNA: trigger of sepsis, mediator of protection, or both?. *Scandinavian Journal of Infectious Diseases*, **2003**, 35, 653-9		38
96	Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. *International Immunology*, **2003**, 15, 577-91	4.9	50
95	Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. *Infection and Immunity*, **2003**, 71, 4398-404	3.7	21
94	CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. *Journal of Immunology*, **2003**, 170, 4061-8	5.3	67
93	CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. *Cancer Research*, **2003**, 63, 394-9	10.1	81
92	CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. *Clinical Cancer Research*, **2003**, 9, 3105-14	12.9	100
91	Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. *European Journal of Immunology*, **2002**, 32, 1212-22	6.1	127
90	Applications of CpG Motifs from Bacterial DNA in Cancer Immunotherapy **2002**, 268-286		1
89	Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. *Nature Immunology*, **2002**, 3, 499	19.1	723
88	Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA. *Oligonucleotides*, **2002**, 12, 327-40		12
87	Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. *Oligonucleotides*, **2002**, 12, 165-75		50
86	B cells express Ly-6C in a Th1 but not Th2 cytokine environment. *Journal of Interferon and Cytokine Research*, **2002**, 22, 799-806	3.5	6

85	Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. *Journal of Immunology*, **2002**, 168, 4711-20	5.3	179
84	Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. *Oligonucleotides*, **2002**, 12, 155-64		14
83	Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. *Blood*, **2002**, 100, 4169-76	2.2	67
82	CpG motifs in bacterial DNA and their immune effects. *Annual Review of Immunology*, **2002**, 20, 709-60	34.7	2122
81	Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. *Blood*, **2001**, 98, 1217-25	2.2	70
80	Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. *European Journal of Immunology*, **2001**, 31, 2154-63	6.1	733
79	Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. *Journal of Immunological Methods*, **2001**, 247, 83-94	2.5	32
78	Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. *American Journal of Obstetrics and Gynecology*, **2001**, 185, 1174-9	6.4	39
77	Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. *Journal of Immunology*, **2001**, 167, 4878-86	5.3	205
76	Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. *Infection and Immunity*, **2001**, 69, 1643-9	3.7	135
75	Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. *Journal of Immunology*, **2001**, 167, 2921-8	5.3	72
74	CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. *International Immunology*, **2001**, 13, 1013-20	4.9	36
73	Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. *International Immunology*, **2001**, 13, 1391-404	4.9	68
72	From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. *Oligonucleotides*, **2001**, 11, 181-8		47
71	Bacterial DNA does not increase serum corticosterone concentration or prevent increases induced by other stimuli. *International Immunopharmacology*, **2001**, 1, 1605-14	5.8	12
70	Now I know my CpGs. *Trends in Microbiology*, **2001**, 9, 249-52	12.4	71
69	Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. *Journal of Interferon and Cytokine Research*, **2001**, 21, 621-9	3.5	20
68	CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. *Oligonucleotides*, **2001**, 11, 247-56		89

67	CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. *Oligonucleotides*, **2001**, 11, 333-40		180
66	CpG Oligodeoxynucleotides **2001**, 31, 229-232		5
65	Signal transduction induced by immunostimulatory CpG DNA **2001**, 97-105		
64	Rescue of B cells from apoptosis by immune stimulatory CpG DNA **2001**, 55-61		
63	Identification of CpG oligonucleotide sequences with high induction of IFN-α in plasmacytoid dendritic cells **2001**, 31, 2154		2
62	The role of CpG motifs in innate immunity. *Current Opinion in Immunology*, **2000**, 12, 35-43	7.8	295
61	Immune effects and therapeutic applications of CpG motifs in bacterial DNA. *Immunopharmacology*, **2000**, 48, 303-5		23
60	Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. *Trends in Immunology*, **2000**, 21, 521-6		110
59	Rescue of B cells from apoptosis by immune stimulatory CpG DNA. *Seminars in Immunopathology*, **2000**, 22, 55-61		13
58	Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. *Journal of Immunology*, **2000**, 164, 1617-24	5.3	512
57	APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. *Journal of Immunology*, **2000**, 165, 6244-51	5.3	72
56	CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. *Journal of Immunology*, **2000**, 165, 6889-95	5.3	110
55	Minding the Cs and Gs. *Molecular Therapy*, **2000**, 1, 209-10	11.7	13
54	Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. *Journal of Immunology*, **2000**, 165, 6278-86	5.3	148
53	CpG DNA is an effective oral adjuvant to protein antigens in mice. *Vaccine*, **2000**, 19, 950-7	4.1	88
52	Immune effects and mechanisms of action of CpG motifs. *Vaccine*, **2000**, 19, 618-22	4.1	127
51	CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. *Vaccine*, **2000**, 18, 1920-4	4.1	143
50	Mechanism and function of a newly identified CpG DNA motif in human primary B cells. *Journal of Immunology*, **2000**, 164, 944-53	5.3	530

49	Signal transduction induced by immunostimulatory CpG DNA. *Seminars in Immunopathology*, **2000**, 22, 97-105		8
48	CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. *International Immunology*, **1999**, 11, 2015-24	4.9	79
47	Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. *International Archives of Allergy and Immunology*, **1999**, 118, 457-61	3.7	71
46	Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. *Immunological Reviews*, **1999**, 168, 217-39	11.3	46
45	Mechanisms and therapeutic applications of immune stimulatory cpG DNA **1999**, 84, 113-20		58
44	Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **1999**, 1489, 107-16		113
43	Direct Immunologic activities of CpG DNA and implications for gene therapy. *Journal of Gene Medicine*, **1999**, 1, 56-63	3.5	9
42	A possible cause of joint destruction in septic arthritis. *Arthritis Research*, **1999**, 1, 3-4		14
41	CpG DNA: a novel immunomodulator. *Trends in Microbiology*, **1999**, 7, 64-5	12.4	35
40	Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. *Vaccine*, **1999**, 17, 3065-71	4.1	124
39	CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. *Journal of Allergy and Clinical Immunology*, **1999**, 104, 1258-64	11.5	124
38	Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus **1999**, 79-100		1
37	Direct immunologic activities of CpG DNA and implications for gene therapy. *Journal of Gene Medicine*, **1999**, 1, 56-63	3.5	97
36	How to Exclude Immunostimmulatory and Other Nonantisense Effects of Antisense Oligonucleotides. *Perspectives in Antisense Science*, **1999**, 79-89		1
35	CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. *Vaccine*, **1998**, 16, 1216-24	4.1	247
34	The role of CpG dinucleotides in DNA vaccines. *Trends in Microbiology*, **1998**, 6, 23-7	12.4	214
33	The CpG motif: implications for clinical immunology. *BioDrugs*, **1998**, 10, 341-6	7.9	13
32	Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. *Oligonucleotides*, **1998**, 8, 351-6		57

31	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. *Blood*, **1998**, 92, 3730-3736	2.2	113
30	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. *Blood*, **1998**, 92, 3730-3736	2.2	2
29	Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. *Journal of Interferon and Cytokine Research*, **1997**, 17, 781-8	3.5	43
28	Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. *Oligonucleotides*, **1997**, 7, 115-23		12
27	CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. *Journal of Experimental Medicine*, **1997**, 186, 1623-31	16.6	883
26	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. *Blood*, **1997**, 89, 2994-2998	2.2	171
25	Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. *Clinical Immunology and Immunopathology*, **1997**, 84, 185-93		242
24	Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. *Trends in Microbiology*, **1996**, 4, 73-6	12.4	116
23	An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. *Translational Research*, **1996**, 128, 128-33		101
22	Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. *Oligonucleotides*, **1996**, 6, 133-9		75
21	CpG DNA: a pathogenic factor in systemic lupus erythematosus?. *Journal of Clinical Immunology*, **1995**, 15, 284-92	5.7	145
20	CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature*, **1995**, 374, 546-9	50.4	3023
19	Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. *Gastroenterology*, **1995**, 109, 1882-9	13.3	11
18	Potential of Antisense Technology in the Treatment of Immunological Disorders. *BioDrugs*, **1995**, 4, 169-179		3
17	Retroviruses and Their Roles in Chronic Inflammatory Diseases and Autoimmunity **1995**, 491-603		16
16	Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates. *Nucleic Acids Research*, **1994**, 22, 5416-24	20.1	44
15	Role of endogenous retroviruses in autoimmune diseases. *Tohoku Journal of Experimental Medicine*, **1994**, 173, 105-14	2.4	4
14	Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. *Antisense Research and Development*, **1994**, 4, 295-7		16

13	Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. *Clinical Immunology and Immunopathology*, **1993**, 67, 130-6		33
12	Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. *Antisense Research and Development*, **1993**, 3, 53-66		206
11	Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. *Antisense Research and Development*, **1992**, 2, 325-30		31
10	Heterogeneous expression and coordinate regulation of endogenous retroviral sequences in human peripheral blood mononuclear cells. *AIDS Research and Human Retroviruses*, **1992**, 8, 1991-8	1.6	39
9	Molecular aspects of systemic lupus erythematosus: murine endogenous retroviral expression. *DNA and Cell Biology*, **1992**, 11, 253-7	3.6	6
8	Applications of antisense oligodeoxynucleotides in immunology and autoimmunity research. *ImmunoMethods*, **1992**, 1, 191-202		10
7	Endogenous retroviruses: potential etiologic agents in autoimmunity. *FASEB Journal*, **1992**, 6, 2537-44	0.9	130
6	Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. *Antisense Research and Development*, **1991**, 1, 161-71		87
5	Theoretical and experimental approaches to generalized autoimmunity. *Immunological Reviews*, **1990**, 118, 129-63	11.3	72
4	Retroviruses and autoimmunity. *Journal of Autoimmunity*, **1990**, 3, 137-66	15.5	97
3	Expression of an endogenous retroviral transcript is associated with murine lupus. *Arthritis and Rheumatism*, **1989**, 32, 322-9		19
2	Increased expression of novel full-length endogenous mink cell focus-forming-related transcripts in autoimmune mouse strains. *Virology*, **1988**, 162, 274-6	3.6	21
1	Immunostimulatory Potential of Silencing RNAs Can Be Mediated by a Non-Uridine-Rich Toll-Like Receptor 7 Motif. *Oligonucleotides*,121102072334007		